New cancer drug enters first human trials for Tough-to-Treat tumors
NCT ID NCT05306132
Summary
This is the first time a new cancer drug called ASKC202 is being tested in people. The study aims to find a safe dose and see if the drug, given alone or with another drug (ASK120067), shows early signs of helping patients with advanced solid tumors that have not responded to standard treatments. It will enroll about 150 adults to check for side effects and how the drug behaves in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital Affiliated to Tongji University
RECRUITINGShanghai, Shanghai Municipality, China
Contact
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, China
Contact
-
Xiangya Hospital Central South University
RECRUITINGChangsha, Hunan, China
Contact
Conditions
Explore the condition pages connected to this study.